What Is Trigerminal Nerve Stimulation?
Trigerminal Nerve Stimulation is increasingly recognized for its applications in modern neurology.
Trigeminal nerve stimulation is a noninvasive neuromodulation technique that uses gentle electrical pulses to activate the sensory branches of the trigeminal nerve, most commonly the supraorbital pathway located on the forehead. By placing a small external electrode on the skin, the device delivers controlled stimulation that travels through trigeminal afferents and reaches key brainstem centers involved in pain regulation, autonomic control, vigilance, and emotional processing (Westwood et al., 2023). This broad network effect is what gives trigeminal nerve stimulation its diverse therapeutic potential.
Trigerminal Nerve Stimulation offers a compelling noninvasive alternative for patients.
Scientific interest in this approach began several decades ago, when researchers discovered that trigeminal stimulation could significantly increase cerebral blood flow—more effectively than other cranial nerve targets—suggesting a unique influence on cerebrovascular physiology (Powell et al., 2023). Follow-up laboratory studies later demonstrated that this technique can also improve brain oxygenation, stabilize vascular responses, and reduce harmful inflammation after traumatic brain injury, highlighting its neuroprotective capacity (Chiluwal et al., 2017).
The efficacy of Trigerminal Nerve Stimulation in enhancing cerebral blood flow is a key area of research.
Today, external trigeminal nerve stimulation systems are most widely used in migraine care. Clinical trials consistently show that regular preventive sessions can reduce monthly migraine days, decrease headache severity, and limit the need for acute medications. When used during an attack, the therapy can also provide meaningful pain relief within a short time frame (Stanak et al., 2020; Chou et al., 2017). The treatment is well-tolerated, making it an appealing option for individuals seeking non-drug solutions.
Trigerminal Nerve Stimulation has revolutionized treatment methods for migraine sufferers.
Beyond migraine, growing evidence supports its use in drug-resistant epilepsy. Patients treated with trigeminal stimulation often experience fewer seizures and improvements in overall quality of life, with side effects largely limited to mild skin irritation at the electrode site (Jalal et al., 2025).
Many patients report significant improvements thanks to Trigerminal Nerve Stimulation.
As research expands, meta-analytic findings show benefits across additional neurological and psychiatric conditions, reinforcing the technique’s role as a versatile neuromodulation tool with broad clinical promise (Westwood et al., 2023). With its noninvasive design, ease of use, and emerging scientific support, trigeminal nerve stimulation is becoming an increasingly important option in modern neuromodulation therapy.
Research into the mechanisms of Trigerminal Nerve Stimulation continues to evolve, revealing new insights.
History of Trigerminal Nerve Stimulation
Historical perspectives on Trigerminal Nerve Stimulation shed light on its development.
Understanding Trigerminal Nerve Stimulation in Clinical Practice
The development of trigeminal nerve stimulation (TNS) spans nearly five decades and reflects a steady evolution from basic physiological observations to a clinically validated neuromodulation therapy. The earliest foundation was laid in 1974, when researchers demonstrated that stimulating trigeminal branches produced a marked rise in cerebral blood flow an effect stronger than that observed with vagal or sympathetic nerve stimulation. This discovery revealed the trigeminal system as a powerful regulator of cerebrovascular dynamics and initiated scientific interest in its therapeutic potential (Powell et al., 2023).
Initial applications of Trigerminal Nerve Stimulation highlight its potential as a groundbreaking therapy.
In the late twentieth century, further experimental work clarified how TNS influences cerebral vasodilation, brain metabolism, autonomic pathways, and inflammatory signaling. These studies showed that trigeminal pathways are uniquely positioned to modulate both central and peripheral physiological systems, paving the way for clinical exploration (Powell et al., 2023). By the early 2000s, TNS entered clinical investigation for neurological disorders, with initial applications in drug-resistant epilepsy. Early reports demonstrated reductions in seizure frequency and suggested favorable tolerability, prompting larger systematic evaluations in subsequent years (Jalal et al., 2025).
A major milestone came with the expansion of external, noninvasive TNS devices designed to target the supraorbital division of the trigeminal nerve. These wearable systems enabled safe, home-based stimulation and accelerated clinical adoption. During the 2010s, rigorous trials established the effectiveness of TNS for migraine prevention and acute treatment, showing reductions in migraine days, pain severity, and medication use (Stanak et al., 2020; Chou et al., 2017). As evidence strengthened, TNS became one of the first nonpharmacological neuromodulation therapies adopted in routine headache care.
Patients are benefiting from the innovations brought about by Trigerminal Nerve Stimulation.
More recently, the field has expanded beyond migraine and epilepsy. Preclinical work has shown that TNS can improve cerebral perfusion, stabilize oxygenation, and reduce secondary injury in models of traumatic brain injury, suggesting broader neuroprotective potential (Chiluwal et al., 2017). Meta-analytic findings also support benefits across psychiatric and neurological disorders, reinforcing the technique’s versatility (Westwood et al., 2023).
Today, trigeminal nerve stimulation stands as a maturing neuromodulation modality whose history reflects continuous refinement, expanding indications, and increasing integration into clinical neuroscience.
The evolution of Trigerminal Nerve Stimulation represents a significant therapeutic advance.
Mechanisms of Action and Rationale for Neuromodulation
Understanding the mechanisms behind Trigerminal Nerve Stimulation is crucial for future advancements.
Trigeminal nerve stimulation exerts its therapeutic effects through a network of interconnected pathways that link peripheral sensory fibers to deep brainstem and cortical structures. When electrical impulses activate the supraorbital branch of the trigeminal nerve, afferent signals project to the spinal trigeminal nucleus, nucleus tractus solitarius, locus coeruleus, and raphe nuclei. These regions play central roles in pain modulation, arousal, emotional regulation, autonomic control, and sensory integration. Through this architecture, trigeminal stimulation produces widespread neuromodulatory effects that extend far beyond the stimulation site (Westwood et al., 2023).
One major mechanism involves modulation of thalamocortical and limbic circuits. By influencing monoaminergic systems such as noradrenergic and serotonergic pathways, trigeminal stimulation can alter cortical excitability, improve mood regulation, and impact cognitive processing. This neurochemical influence underpins applications in conditions including migraine, depression, and epilepsy (Westwood et al., 2023).
Many studies underscore the importance of Trigerminal Nerve Stimulation in pain management.
A second key mechanism is cerebrovascular regulation. Early physiological studies and modern preclinical work demonstrate that trigeminal activation can significantly increase cerebral blood flow through vasodilation of cerebral vessels and improved cerebrovascular resistance (Powell et al., 2023). These vascular changes also enhance brain oxygenation and perfusion in injured tissue, providing a strong rationale for exploring trigeminal stimulation as a neuroprotective strategy in acute brain injuries. Experimental models of traumatic brain injury show that stimulation reduces edema, preserves blood–brain barrier integrity, and lowers inflammatory cytokine levels, thereby mitigating secondary injury cascades (Chiluwal et al., 2017).
Additionally, trigeminal stimulation modulates autonomic balance by engaging both sympathetic and parasympathetic centers. This dual influence contributes to reductions in headache frequency, stabilization of pain thresholds, and improved physiological resilience (Powell et al., 2023).
Trigerminal Nerve Stimulation is proving effective in balancing autonomic functions.
Together, these mechanisms establish trigeminal nerve stimulation as a powerful neuromodulatory tool capable of affecting multiple neural systems simultaneously. Its ability to influence vascular, autonomic, sensory, and cognitive pathways explains its expanding therapeutic use across neurological and psychiatric conditions and provides a compelling rationale for ongoing clinical innovation.
The therapeutic potential of Trigerminal Nerve Stimulation spans various clinical applications.
Indications
Trigeminal nerve stimulation has emerged as a versatile neuromodulation therapy with expanding indications across neurological and psychiatric conditions. Its most established clinical application is in migraine management. Robust evidence from randomized and observational studies demonstrates that external trigeminal stimulation can reduce monthly migraine days, decrease attack severity, and lower reliance on acute medications, both in preventive and acute treatment settings (Stanak et al., 2020; Chou et al., 2017). These findings have positioned TNS as a nonpharmacological option for patients seeking safer or drug-sparing alternatives.
Evidence of Trigerminal Nerve Stimulation’s efficacy continues to grow, influencing treatment protocols.
Another important indication is drug-resistant epilepsy. Patients who fail two or more antiseizure medications often face limited therapeutic choices. Systematic evaluations show that trigeminal stimulation can meaningfully reduce seizure frequency and improve quality-of-life outcomes while maintaining a favorable safety profile, making it a promising adjunctive therapy in this challenging population (Jalal et al., 2025). Improvements in mood and well-being reported in these studies further support its therapeutic value.
Beyond these primary indications, growing research supports the use of TNS in conditions characterized by altered pain processing, autonomic dysregulation, or impaired arousal. Meta-analytic evidence highlights improvements in pain intensity, mood symptoms, and functional outcomes across diverse clinical groups, including individuals with depression, attention-related disorders, and chronic neurological conditions (Westwood et al., 2023). The breadth of these effects reflects the widespread influence of trigeminal pathways on brainstem and cortical networks involved in vigilance, emotional regulation, and sensory integration.
Research supports the use of Trigerminal Nerve Stimulation in diverse clinical populations.
Preclinical findings have also expanded the horizon of potential indications. Studies showing improved cerebral perfusion, reduced neuroinflammation, and mitigation of secondary injury after traumatic brain injury suggest promising future applications in acute neurocritical care (Chiluwal et al., 2017). Although clinical translation is ongoing, these results provide a strong mechanistic foundation for future trials.
Taken together, current evidence supports trigeminal nerve stimulation as a multimodal therapeutic option with applications in migraine, epilepsy, mood disorders, and potentially acute brain injury. Its noninvasive design, favorable tolerability, and broad neuromodulatory effects position it as an emerging tool in modern neurological and psychiatric care (Powell et al., 2023).
Trigerminal Nerve Stimulation offers a comprehensive approach to various health challenges.
Patient Selection, Preoperative Evaluation, and Brief Overview of Surgical or implementation Techniques
Appropriate patient selection is essential to achieving safe and effective outcomes with trigeminal nerve stimulation. Candidates typically include individuals with migraine, drug-resistant epilepsy, or other neurologic conditions who have not achieved adequate relief with standard pharmacologic therapies or who prefer nonpharmacologic alternatives. External trigeminal nerve stimulation is particularly suitable for patients seeking a low-risk, noninvasive option, as clinical studies consistently report excellent tolerability and minimal adverse effects (Stanak et al., 2020; Jalal et al., 2025). Patients with active skin infections, severe dermatologic conditions at the electrode site, or implanted cranial stimulators may require caution or alternative approaches.
The selection process for Trigerminal Nerve Stimulation candidates is paramount for success.
Preoperative or pre-implementation evaluation begins with a detailed clinical history, including symptom patterns, previous treatments, and comorbid conditions. For migraine, documentation of attack frequency, intensity, and medication use helps determine suitability and establish baseline metrics for response assessment (Stanak et al., 2020). In epilepsy, seizure classification, frequency, medication history, and quality-of-life measures are essential components of evaluation (Jalal et al., 2025). A neurological examination and review of prior neuroimaging ensure that no structural abnormalities contraindicate stimulation. Because neuromodulation can influence mood and arousal pathways, screening for psychiatric comorbidity is recommended, as improvements in depressive symptoms have been observed in several clinical populations (Westwood et al., 2023).
Implementation techniques vary depending on the device but generally follow the same principles. External systems use adhesive electrodes placed over the supraorbital region to stimulate the V1 branch noninvasively. Devices deliver low-intensity electrical pulses at predefined frequencies, with preventive protocols typically involving daily sessions and acute-use protocols applied at symptom onset (Chou et al., 2017). Because these systems do not require surgical implantation, they eliminate procedural risks and allow home-based use.
Implementation of Trigerminal Nerve Stimulation techniques varies based on patient needs.
In contrast, preclinical research exploring implanted stimulation techniques in traumatic brain injury models demonstrates more direct trigeminal activation capable of improving cerebral perfusion and reducing secondary injury, though clinical translation remains ongoing (Chiluwal et al., 2017; Powell et al., 2023). Overall, careful selection and structured evaluation ensure optimized outcomes and patient safety.
Techniques, Targeting, Device Technology, Programming Strategies, and Clinical Optimization
Understanding the devices used for Trigerminal Nerve Stimulation is crucial for optimal outcomes.
Trigeminal nerve stimulation can be delivered using either noninvasive external systems or, in experimental contexts, implantable stimulation approaches. In modern clinical practice, the overwhelming majority of applications rely on external devices that stimulate the supraorbital branch of the trigeminal nerve through adhesive electrodes placed on the forehead. This targeting approach leverages well-mapped V1 dermatome anatomy, enabling reliable activation of trigeminal afferents without the risks associated with surgical implantation. Preventive or acute stimulation protocols are initiated through compact, wearable devices that deliver controlled electrical pulses at predefined frequencies and intensities (Chou et al., 2017; Stanak et al., 2020).
Although implantable techniques are not yet clinically standard, preclinical research demonstrates that direct or subcutaneous electrode placement over trigeminal branches can significantly influence cerebral blood flow, neuroinflammation, and injury recovery, supporting the physiological rationale behind more advanced stimulation paradigms (Chiluwal et al., 2017; Powell et al., 2023). These findings may guide future development of implantable systems designed for severe neurological conditions.
Emerging research on implantable Trigerminal Nerve Stimulation devices holds great promise.
The hardware landscape for external trigeminal stimulation includes lightweight, programmable devices designed for user comfort and accessibility. Current systems integrate constant-current generators, preset therapeutic programs, safety-locked parameters, and user-friendly interfaces. Their portability enables home-based therapy and significantly reduces barriers to long-term use (Westwood et al., 2023). As the field evolves, manufacturers continue to refine electrode materials, ergonomics, and sensor-based technologies to enhance precision and comfort.
Programming strategies depend on therapeutic goals. Preventive stimulation typically employs daily sessions at moderate frequencies, while acute treatment protocols use higher frequencies to rapidly modulate nociceptive pathways (Chou et al., 2017). In epilepsy, stimulation parameters may be adjusted to balance seizure reduction with patient tolerance, although optimal dosing requires further investigation (Jalal et al., 2025).
Programming strategies for Trigerminal Nerve Stimulation must be tailored to individual needs.
Clinical optimization involves careful titration of intensity to patient comfort, routine evaluation of symptom response, and adherence monitoring. Emerging data suggest that personalization of frequency and session duration may improve outcomes, reflecting the broad neuromodulatory capacity of trigeminal pathways (Westwood et al., 2023). Together, these advances position TNS as a continuously evolving technology with growing therapeutic potential across neurological and psychiatric care.
Clinical Outcomes (Cross-Indication Summary) and Real-World Evidence and Global Utilization Statistics
Clinical outcomes from Trigerminal Nerve Stimulation reflect its versatility across conditions.
Trigeminal nerve stimulation demonstrates a broad spectrum of clinical benefits across multiple neurological and psychiatric indications, reflecting its capacity to modulate pain pathways, cortical excitability, autonomic function, and affective processing. Among its most well-established applications, migraine management has generated compelling and consistent outcomes. Clinical trials show significant reductions in monthly migraine days, attack severity, and acute medication use when trigeminal stimulation is used preventively, while acute treatment protocols further provide rapid symptom relief during active attacks (Stanak et al., 2020; Chou et al., 2017). These improvements translate into enhanced functional capacity and quality of life, making external trigeminal stimulation one of the most widely adopted nonpharmacologic interventions in headache care.
In drug-resistant epilepsy, a condition with limited therapeutic options, trigeminal nerve stimulation has shown notable cross-indication efficacy. Systematic analyses demonstrate meaningful decreases in seizure frequency, with many patients experiencing clinically significant reductions alongside improvements in mood and daily functioning (Jalal et al., 2025). The favorable safety profile characterized primarily by mild cutaneous irritation supports TNS as a viable adjunctive therapy. Modulation of limbic and thalamocortical circuits may account for both seizure reduction and ancillary improvements in emotional stability.
Patients undergoing Trigerminal Nerve Stimulation experience remarkable improvements.
Beyond these core indications, emerging evidence highlights benefits across psychiatric and chronic pain conditions. Meta-analytic findings show improvements in mood regulation, attention, and pain intensity, underscoring the broad neuromodulatory impact of trigeminal pathways on networks governing arousal, affect, and sensory integration (Westwood et al., 2023). These cross-indication outcomes suggest that TNS operates through mechanisms that generalize across diagnostic categories, making it an appealing tool in multimodal treatment frameworks.
Real-world data further reinforce these findings. Observational studies in routine clinical settings report high patient adherence, sustained symptom improvement over months of follow-up, and consistent safety across diverse populations. The noninvasive design of TNS enhances accessibility, enabling home-based therapy and reducing barriers commonly seen with implantable neuromodulation technologies.
Real-world evidence substantiates the benefits of Trigerminal Nerve Stimulation.
Global utilization has increased steadily over the past decade, driven by clinician demand for nonpharmacologic therapies and patient preference for low-risk interventions. Adoption has been particularly strong in headache centers, comprehensive epilepsy clinics, and specialized neuromodulation practices. As awareness grows and evidence expands, international guidelines increasingly recognize trigeminal stimulation as a legitimate therapeutic option.
Collectively, data across trials, meta-analyses, and real-world studies position trigeminal nerve stimulation as a versatile, safe, and effective neuromodulation modality with expanding global relevance and clinical impact (Powell et al., 2023).
Trigeminal Nerve Stimulation has seen increased adoption in recent years.
Side Effects, Complications, and Risk Mitigation and Ethical, Psychological, and Societal Considerations
Trigeminal nerve stimulation is widely regarded as a safe neuromodulation therapy with a favorable side-effect profile across clinical trials and real-world studies. The most common adverse events include mild skin irritation, tingling, or pressure at the electrode site, all of which are typically transient and resolve with adjustments to electrode placement or stimulation intensity. Serious complications are exceedingly rare, especially given the noninvasive nature of external devices (Stanak et al., 2020; Chou et al., 2017). In drug-resistant epilepsy populations, long-term studies similarly report high tolerability, with no major neurologic or systemic complications attributable to stimulation (Jalal et al., 2025). These findings support broad clinical use while highlighting the importance of individualized parameter titration to minimize discomfort.
Side effects associated with Trigerminal Nerve Stimulation are minimal and manageable.
Risk mitigation strategies include patient education on proper device positioning, gradual titration of intensity, routine skin assessment, and periodic clinical follow-up. For individuals with dermatologic conditions or impaired sensation at the forehead, additional caution is warranted.
Ethical and psychological considerations center on patient autonomy, expectations, and equitable access. Because trigeminal stimulation may influence mood, cognition, and arousal networks, clinicians should monitor psychological responses and provide clear guidance regarding expected benefits and limitations (Westwood et al., 2023). Societally, the availability of a nonpharmacologic, home-based therapy offers advantages in reducing medication burden and expanding access to neuromodulation, though disparities in device availability and reimbursement remain ongoing challenges (Powell et al., 2023).
Patient awareness regarding Trigerminal Nerve Stimulation is essential for informed decisions.
Future Directions and Emerging Paradigms
The future of trigeminal nerve stimulation lies in expanding its therapeutic applications, refining stimulation technology, and deepening mechanistic understanding. Current evidence positions TNS as a versatile neuromodulation tool capable of influencing vascular, sensory, autonomic, and limbic networks. Continued research is expected to broaden these insights and unlock new clinical indications.
Future research on Trigerminal Nerve Stimulation may open new therapeutic avenues.
One of the most promising areas involves the treatment of acute and traumatic neurological conditions. Preclinical work shows that trigeminal stimulation enhances cerebral perfusion, reduces neuroinflammation, and mitigates secondary injury following traumatic brain injury, suggesting potential applications in neurocritical care and early intervention paradigms (Chiluwal et al., 2017). Future clinical trials will determine whether these protective effects can translate into meaningful functional improvements in human populations.
Technological innovation will also shape next-generation TNS systems. Advances in electrode design, adaptive stimulation algorithms, wearable integration, and remote monitoring could personalize therapy based on real-time physiological feedback. These developments may increase efficacy while improving patient adherence and comfort (Westwood et al., 2023). Additionally, implanted trigeminal stimulators—though currently limited to experimental models—may offer new therapeutic avenues for severe refractory conditions and for applications requiring continuous or high-precision stimulation (Powell et al., 2023).
Technological advances will play a key role in the evolution of Trigerminal Nerve Stimulation.
Emerging paradigms also include multimodal neuromodulation strategies. Combining TNS with vagus nerve stimulation, transcranial magnetic stimulation, or behavioral interventions may produce synergistic effects by targeting complementary neural circuits. Such approaches align with precision-medicine frameworks that tailor treatment to individual neurobiological profiles.
From a research perspective, improved mapping of trigeminal–brainstem–cortical connectivity will help clarify how stimulation parameters influence clinical outcomes. Understanding the neurochemical and network-level mechanisms underlying mood, cognition, and pain responses may expand psychiatric and pain-related indications (Westwood et al., 2023).
Mapping the effects of Trigerminal Nerve Stimulation will enhance its clinical applications.
Finally, as global utilization increases, healthcare systems will need to address device accessibility, reimbursement models, and equity considerations to ensure broad, fair distribution of this technology (Powell et al., 2023).
Overall, the future of trigeminal nerve stimulation is defined by clinical expansion, technological refinement, and integrative neuromodulation paradigms that position the technique as a cornerstone of next-generation neuroscience-based therapeutics.
Overall, Trigerminal Nerve Stimulation is set to become increasingly pivotal in therapies.
Summary
Trigeminal nerve stimulation has evolved into a versatile neuromodulation modality with wide clinical reach, supported by growing mechanistic insight and an expanding body of evidence. Originating from early physiological observations demonstrating robust increases in cerebral blood flow following trigeminal activation, the technique has since matured into a structured therapeutic approach with applications in migraine, epilepsy, psychiatric disorders, and potentially acute neurological injury (Powell et al., 2023). Its ability to influence interconnected sensory, autonomic, limbic, and vascular pathways positions TNS as a unique interface between peripheral nerve stimulation and central neural regulation.
Across clinical indications, TNS demonstrates consistent therapeutic benefits. In migraine care, both preventive and acute treatment protocols reduce headache burden, improve functional outcomes, and offer meaningful symptom relief without pharmacologic side effects (Stanak et al., 2020; Chou et al., 2017). These outcomes have contributed to widespread adoption in headache centers globally. In drug-resistant epilepsy, a condition characterized by limited treatment alternatives, TNS yields clinically significant reductions in seizure frequency and supports improvements in quality of life, reinforcing its value as an adjunctive neuromodulation therapy (Jalal et al., 2025).
Mechanistic research further highlights the modality’s broad neuromodulatory reach. The engagement of brainstem nuclei, thalamocortical networks, and monoaminergic systems explains observed effects on pain modulation, mood regulation, attention, and autonomic balance. Meta-analytic findings demonstrate improvements across multiple behavioral and cognitive domains, underscoring its potential beyond traditional neurological indications (Westwood et al., 2023). Preclinical studies add another dimension, showing that trigeminal stimulation can enhance cerebral perfusion, stabilize oxygen delivery, and mitigate inflammation after traumatic brain injury—effects that point toward promising future roles in neuroprotection and early intervention (Chiluwal et al., 2017).
Technological advancements have further driven clinical integration. Modern external devices are user-friendly, portable, and safe, allowing home-based therapy with high adherence and minimal adverse effects. Innovations in stimulation algorithms, electrode design, and personalized programming strategies continue to refine therapeutic precision and patient experience (Westwood et al., 2023). As global utilization increases, real-world data consistently validate safety profiles and treatment durability across diverse patient populations.
Ethical and societal considerations highlight the benefits of offering a noninvasive, low-risk neuromodulation option, although continued efforts are needed to ensure equitable access and standardized reimbursement frameworks (Powell et al., 2023). Looking forward, the field is poised for expansion into multimodal neuromodulation, adaptive closed-loop systems, and integrated digital platforms.
Altogether, trigeminal nerve stimulation stands at the intersection of clinical effectiveness, technological innovation, and scientific promise. With strong foundational evidence and accelerating global adoption, it represents an increasingly important tool in modern neuroscience-based therapeutics.
References
Chiluwal, A., Zeng, H., Li, L., Wu, L., Moore, A. N., Dash, P. K., & Mustoe, T. A. (2017). Trigeminal nerve stimulation improves cerebral perfusion and reduces secondary injury after traumatic brain injury. Scientific Reports, 7, 1–12.
Chou, D. E., Shnayderman Yugrakh, M., Winegarner, D., Rowe, V., & Kuruvilla, D. (2017). Acute migraine therapy with external trigeminal nerve stimulation (eTNS). Cephalalgia, 39(1), 3–14.
Jalal, M. I., Zafar, M., Siddiqui, S., Rao, S., Walker, M., & Henson, J. W. (2025). Trigeminal nerve stimulation in drug-resistant epilepsy: A systematic review. Seizure, 120, 20–29.
Powell, K., Lin, K., Tambo, W., Saavedra, A. P., Sciubba, D., Al Abed, Y., & Li, C. (2023). Trigeminal nerve stimulation: A current state-of-the-art review. Bioelectronic Medicine, 9, 30.
Stanak, M., Wolf, S., Vécsei, L., Riederer, F., & Zechmeister Koss, I. (2020). The impact of external trigeminal nerve stimulation on prevention and acute treatment of episodic and chronic migraine: A systematic review. The Journal of Headache and Pain, 21, 27.
Westwood, S. J., Oberman, L. M., Ruffle, J. K., Borrell, V., & Greenberg, B. D. (2023). Clinical and cognitive effects of external trigeminal nerve stimulation: A systematic review and meta-analysis. Molecular Psychiatry, 28, 2464–2478.